First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Phase I dose-escalation study including pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I., Ramanathan, R. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035790/
https://www.ncbi.nlm.nih.gov/pubmed/27672108
http://dx.doi.org/10.1093/annonc/mdw282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035790/
https://www.ncbi.nlm.nih.gov/pubmed/27672108
http://dx.doi.org/10.1093/annonc/mdw282

Ejemplares similares